Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases

American Journal of Drug and Alcohol Abuse

Volumn 33, Issue 6, 2007, Pages 869-874

  Bruce, Robert D ^a   Altice, Frederick L ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

Abnormal transaminases; Acute hepatitis C; Buprenorphine; Clinical care; Opioid agonist therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; OPIATE;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEMALE; HELP SEEKING BEHAVIOR; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LABORATORY TEST; LIVER LEVEL; MALE; MASS SCREENING; OPIATE ADDICTION;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIPOLAR DISORDER; BUPRENORPHINE; COCAINE-RELATED DISORDERS; FEMALE; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; NALOXONE; NARCOTIC ANTAGONISTS; NEEDLE SHARING; OPIOID-RELATED DISORDERS; RNA, VIRAL; TRANSAMINASES;

EID: 36248940775     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990701653875     Document Type: Article

References (13)

1. Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. MMWR 1998; Suppl RR-19, 47(40):1-39.
2. Hepatitis C. MMWR 2002; Suppl RR-7, 51(18):64-66.
3. Liguori A, Morse WH, Bergman J. Respiratory effects of opioid full and partial agonists in rhesus monkeys. J Pharma Exp Therap 1996; 277(1):462-472.
4. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharma Therap 1994; 55(5):569-580.
5. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. New England Journal of Medicine 2002; 347(11):817-823.
6. Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV prevention. Clin Infect Dis 2006, 43 Suppl 3, S179-83.
7. Berson A, Gervais A, Cazals D, Boyer N, Durand F, Bernuau J, Marcellin P, Degott C, Valla D, Pessayre D. Hepatitis after intravenous buprenorphine misuse in heroin addicts. Journal of Hepatology 2001; 34(2):346-350.
8. Berson A, Fau D, Fornacciari R, Degove-Goddard P, Sutton A, Descatoire V, Haouzi D, Letteron P, Moreau A, Feldmann G, Pessayre D. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. Journal of Hepatology 2001; 34(2):261-269.
9. Houdret N, Asnar V, Szostak-Talbodec N, Leteurtre E, Humbert L, Lecomte-Houcke M, Lhermitte M, Paris JC. Hepatonephritis and massive ingestion of buprenorphine. Acta Clinica Belgica - Supplementum 1999; 1:29-31.
10. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D. Buprenorphine/Naloxone Collaborative Study, G. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 2003; 349(10):949-958.
11. Johnson RE, Chutuape MA, Strain, EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.[see comment]. New England Journal of Medicine 2000; 343(18):1290-1297.
12. O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting. A randomized trial. Annals of Internal Medicine 1997; 127(7):526-530.
13. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug & Alcohol Dependence 1995; 40(1):17-25.